Case of alemtuzumab-related alopecia areata management in MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 22, 2018
- Accepted in final form August 8, 2018
- First Published October 19, 2018.
Author Disclosures
- Jillian K. Chan, MD,
- Anthony L. Traboulsee, MD and
- Ana-Luiza Sayao, MD
- Jillian K. Chan, MD,
NONE
NONE
Speaker for the MS Society of Canada. Presented MS 101 Education Event in Nanaimo, BC, Canada and received travel reimbursement only.
NONE
NONE
NONE
NONE
I consulted for Roche one time.
NONE
I received a fellowship grant from Biogen for my first year, and I received a fellowship grant from the Canadian network of MS clinics for my second year.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anthony L. Traboulsee, MD and
1. Sanofi Genzyme (commercial) 2. MS Society of Canada (non profit) 3. Canadian Institute for Health Research (non profit) 4. CADTH (non profit)
NONE
1. Sanofi Genzyme (commercial) 2. Biogen (commercial) 3. Teva (commercial) 4. Novartis (commercial) 5. Hoffman la Roche (commercial) 6. MS Society of Canada (non profit) 7. Consortium of MS Centers (non profit)
NONE
NONE
NONE
NONE
A. Traboulsee reports receiving consulting fees from (1) Biogen (commercial) (2) Novartis (commercial) (3) Hoffman la Roche (commercial) (4) Sanofi Genzyme (commercial) (5) Teva Innovation (commercial) (6) Chugai (commercial)
NONE
NONE
NONE
A Traboulsee has been a principal investigator on clinical trials funded by Hoffman la Roche, Chugai, Novartis, Biogen and Sanofi Genzyme.
(1) Canadian Institute for Health Research, Principal Investigator 2012-2018 (2) Multiple Sclerosis Society of Canada, Principal Investigator 2012-2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ana-Luiza Sayao, MD
NONE
NONE
Speaker Honorarium from Merck-Serono
NONE
NONE
NONE
NONE
Advisory board consultancy for Merck-Serono, Novartis, Biogen, Roche and Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Medicine (Neurology), University of British Columbia, Vancouver, British Columbia, Canada.
- Correspondence
Dr. Chan jillian.chan{at}ubc.ca
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Clinical/Scientific Notes
Case of alopecia universalis associated with alemtuzumab treatment in MSVerena Isabell Leussink, Julia Reifenberger, Hans-Peter Hartung et al.Neurology: Neuroimmunology & Neuroinflammation, March 16, 2018 -
Article
Vitiligo after alemtuzumab treatmentSecondary autoimmunity is not all about B cellsTobias Ruck, Steffen Pfeuffer, Andreas Schulte-Mecklenbeck et al.Neurology, November 07, 2018 -
Article
Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSFNora Möhn, Steffen Pfeuffer, Tobias Ruck et al.Neurology: Neuroimmunology & Neuroinflammation, December 11, 2019 -
Article
Mitigating alemtuzumab-associated autoimmunity in MSA “whack-a-mole” B-cell depletion strategyEthan Meltzer, Sarah Campbell, Benjamin Ehrenfeld et al.Neurology: Neuroimmunology & Neuroinflammation, August 07, 2020